Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
L124970-10mg | 10mg | In stock | $58.90 | |
L124970-25mg | 25mg | In stock | $71.90 | |
L124970-50mg | 50mg | In stock | $82.90 | |
L124970-100mg | 100mg | In stock | $105.90 | |
L124970-250mg | 250mg | In stock | $238.90 | |
L124970-500mg | 500mg | In stock | $337.90 |
PI3-kinase inhibitor
Synonyms | 154447-36-6|LY294002|LY 294002|2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one|LY-294002|2-morpholino-8-phenyl-4H-chromen-4-one|2-morpholin-4-yl-8-phenyl-4H-chromen-4-one|2-morpholin-4-yl-8-phenylchromen-4-one|2-(morpholin-4-yl)-8-phenyl-4H-chromen-4-one |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | LY294002 is a potent inhibitor of PI 3-kinase, a protein in the phosphoinositide 3-kinase family of intercellular signal regulating enzymes. This compound is selective for PI 3-kinase p110 β (PI 3-Kβ) and PI 3-kinase p110 α (PI 3-Kα), although it will inh |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Pubchem Sid | 488179813 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488179813 |
IUPAC Name | 2-morpholin-4-yl-8-phenylchromen-4-one |
INCHI | InChI=1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2 |
InChi Key | CZQHHVNHHHRRDU-UHFFFAOYSA-N |
Canonical SMILES | C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4 |
Isomeric SMILES | C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4 |
PubChem CID | 3973 |
Molecular Weight | 307.35 |
PubChem SID | 488179813 |
---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
H2427172 | Certificate of Analysis | Aug 14, 2024 | L124970 |
H2427173 | Certificate of Analysis | Aug 14, 2024 | L124970 |
H2427175 | Certificate of Analysis | Aug 14, 2024 | L124970 |
I2224270 | Certificate of Analysis | Jul 04, 2024 | L124970 |
A2429198 | Certificate of Analysis | Jan 12, 2024 | L124970 |
A2429186 | Certificate of Analysis | Jan 12, 2024 | L124970 |
A2429199 | Certificate of Analysis | Jan 12, 2024 | L124970 |
A2429197 | Certificate of Analysis | Jan 12, 2024 | L124970 |
A2429196 | Certificate of Analysis | Jan 12, 2024 | L124970 |
A2429195 | Certificate of Analysis | Jan 12, 2024 | L124970 |
A2429194 | Certificate of Analysis | Jan 12, 2024 | L124970 |
A2429192 | Certificate of Analysis | Jan 12, 2024 | L124970 |
A2429191 | Certificate of Analysis | Jan 12, 2024 | L124970 |
A2429190 | Certificate of Analysis | Jan 12, 2024 | L124970 |
A2429189 | Certificate of Analysis | Jan 12, 2024 | L124970 |
A2429188 | Certificate of Analysis | Jan 12, 2024 | L124970 |
I2118363 | Certificate of Analysis | Jan 02, 2024 | L124970 |
K2309266 | Certificate of Analysis | Oct 25, 2023 | L124970 |
K2309265 | Certificate of Analysis | Oct 25, 2023 | L124970 |
K2309264 | Certificate of Analysis | Oct 25, 2023 | L124970 |
K2309263 | Certificate of Analysis | Oct 25, 2023 | L124970 |
I2118361 | Certificate of Analysis | Jul 07, 2023 | L124970 |
E2322308 | Certificate of Analysis | Apr 27, 2023 | L124970 |
E2322341 | Certificate of Analysis | Apr 27, 2023 | L124970 |
E2322305 | Certificate of Analysis | Apr 27, 2023 | L124970 |
E2322301 | Certificate of Analysis | Apr 27, 2023 | L124970 |
E2322297 | Certificate of Analysis | Apr 27, 2023 | L124970 |
E2322284 | Certificate of Analysis | Apr 27, 2023 | L124970 |
E2322306 | Certificate of Analysis | Apr 27, 2023 | L124970 |
E2322259 | Certificate of Analysis | Apr 27, 2023 | L124970 |
E2322283 | Certificate of Analysis | Apr 27, 2023 | L124970 |
E2322269 | Certificate of Analysis | Apr 27, 2023 | L124970 |
E2322278 | Certificate of Analysis | Apr 27, 2023 | L124970 |
C2323005 | Certificate of Analysis | Jul 20, 2022 | L124970 |
I2224272 | Certificate of Analysis | Jul 20, 2022 | L124970 |
I2224271 | Certificate of Analysis | Jul 20, 2022 | L124970 |
I2224269 | Certificate of Analysis | Jul 20, 2022 | L124970 |
I2224268 | Certificate of Analysis | Jul 20, 2022 | L124970 |
Solubility | Soluble in DMSO (25 mg/ml warm), ethanol (25 mg/ml warm), chloroform, water (< 50 ug/ml) at 25 °C, PBS pH 7.2 (< 50 ug/ml), DMF (~16 mg/ml ), and DMSO:PBS(1:1, pH 7.2) (~0.5 mg/ml ). |
---|---|
Sensitivity | Heat Sensitive |
Melt Point(°C) | 184 °C |
1. Cabezas-Cruz A et al.. (2017) Anaplasma phagocytophilum Infection Subverts Carbohydrate Metabolic Pathways in the Tick Vector, Ixodes scapularis.. Front Cell Infect Microbiol, 7 (23). [PMID:28229048] |
2. Wu HB et al.. (2017) Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells.. Autophagy, 13 (9): (1528-1542). [PMID:28812437] |
3. Ribeiro FF et al.. (2016) Axonal elongation and dendritic branching is enhanced by adenosine A2A receptors activation in cerebral cortical neurons.. Brain Struct Funct, 221 (5): (2777-99). [PMID:26068054] |
4. Wu N et al.. (2021) Berberine ameliorates neuronal AD-like change via activating Pi3k/PGCε pathway.. Biofactors, 47 (4): (587-599). [PMID:33740285] |
5. Jiang T et al.. (2022) Application of Bone Marrow Mesenchymal Stem Cells Effectively Eliminates Endotoxemia to Protect Rat from Acute Liver Failure Induced by Thioacetamide.. Tissue Eng Regen Med, 19 (2): (403-415). [PMID:35122584] |
6. Lan X et al.. (2017) Bisphenol A exposure promotes HTR-8/SVneo cell migration and impairs mouse placentation involving upregulation of integrin-ß1 and MMP-9 and stimulation of MAPK and PI3K signaling pathways.. Oncotarget, 8 (31): (51507-51521). [PMID:28881663] |
7. Song XL et al.. (2017) Casticin induces apoptosis and G0/G1 cell cycle arrest in gallbladder cancer cells.. Cancer Cell Int, 17 (9). [PMID:28070171] |
8. Xu Z et al.. (2016) C-C Motif Chemokine Receptor 9 Exacerbates Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction.. J Am Heart Assoc, 5 (5): [PMID:27146447] |
9. Jiang C et al.. (2019) CSNK2A1 Promotes Gastric Cancer Invasion Through the PI3K-Akt-mTOR Signaling Pathway.. Cancer Manag Res, 11 (10135-10143). [PMID:31819646] |
10. Hossain ME et al.. (2017) Direct exposure to mild heat promotes proliferation and neuronal differentiation of neural stem/progenitor cells in vitro.. PLoS One, 12 (12): (e0190356). [PMID:29287093] |
11. Fukushima T et al.. (2019) Discrimination of Dormant and Active Hematopoietic Stem Cells by G0 Marker Reveals Dormancy Regulation by Cytoplasmic Calcium.. Cell Rep, 29 (12): (4144-4158.e7). [PMID:31851939] |
12. Cao S et al.. (2022) Effects of cGMP/Akt/GSK-3β signaling pathway on atrial natriuretic peptide secretion in rabbits with rapid atrial pacing.. Front Physiol, 13 (861981). [PMID:36060704] |
13. Dong L et al.. (2019) FGF10 Enhances Peripheral Nerve Regeneration via the Preactivation of the PI3K/Akt Signaling-Mediated Antioxidant Response.. Front Pharmacol, 10 (1224). [PMID:31680984] |
14. Yan X et al.. (2016) Ginsenoside Rd. promotes non-amyloidogenic pathway of amyloid precursor protein processing by regulating phosphorylation of estrogen receptor alpha.. Life Sci, [PMID:27825720] |
15. Nagae K et al.. (2018) Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K/Akt pathway in keratinocytes.. Diabetes Res Clin Pract, 146 (155-161). [PMID:30367901] |
16. Cheng Y et al.. (2014) High glucose-induced resistance to 5-fluorouracil in pancreatic cancer cells alleviated by 2-deoxy-D-glucose.. Biomed Rep, 2 (2): (188-192). [PMID:24649094] |
17. Ke H et al.. (2020) Hydrogen-Rich Saline Regulates Microglial Phagocytosis and Restores Behavioral Deficits Following Hypoxia-Ischemia Injury in Neonatal Mice via the Akt Pathway.. Drug Des Devel Ther, 14 (3827-3839). [PMID:33061290] |
18. Xu Q et al.. (2022) Interfering with the expression of EEF1D gene enhances the sensitivity of ovarian cancer cells to cisplatin.. BMC Cancer, 22 (628). [PMID:35672728] |
19. Shrestha R et al.. (2014) Lymphocyte-mediated neuroprotection in in vitro models of excitotoxicity involves astrocytic activation and the inhibition of MAP kinase signalling pathways.. Neuropharmacology, 76 Pt A (184-93). [PMID:23831681] |
20. Tanaka Y et al.. (2022) Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcoma.. Sci Rep, 12 (4031). [PMID:35256687] |
21. Tanaka Y et al.. (2021) NECTIN4: A Novel Therapeutic Target for Melanoma.. Int J Mol Sci, 22 (2): [PMID:33478111] |
22. Feng C et al.. (2020) Neuroprotective Effect of Danhong Injection on Cerebral Ischemia-Reperfusion Injury in Rats by Activation of the PI3K-Akt Pathway.. Front Pharmacol, 11 (298). [PMID:32218735] |
23. Guo W et al.. (2017) Neurotrophin-4 induces myelin protein zero expression in cultured Schwann cells via the TrkB/PI3K/Akt/mTORC1 pathway.. Anim Cells Syst (Seoul), 21 (2): (84-92). [PMID:30460055] |
24. Slaninova V et al.. (2016) Notch stimulates growth by direct regulation of genes involved in the control of glycolysis and the tricarboxylic acid cycle.. Open Biol, 6 (2): (150155). [PMID:26887408] |
25. Liu S et al.. (2022) Protection of Human Lens Epithelial Cells from Oxidative Stress Damage and Cell Apoptosis by KGF-2 through the Akt/Nrf2/HO-1 Pathway.. Oxid Med Cell Longev, 2022 (6933812). [PMID:35222803] |
26. Pluteanu F & Cribbs LL. (2011) Regulation and function of Cav3.1 T-type calcium channels in IGF-I-stimulated pulmonary artery smooth muscle cells.. Am J Physiol Cell Physiol, 300 (3): (C517-25). [PMID:21148410] |
27. Zhang J et al.. (2020) SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway.. J Exp Clin Cancer Res, 39 (79). [PMID:32381034] |
28. Guan Y & Wang X. (2021) Salvianic Acid A Regulates High-Glucose-Treated Endothelial Progenitor Cell Dysfunction via the AKT/Endothelial Nitric Oxide Synthase (eNOS) Pathway.. Med Sci Monit, 27 (e928153). [PMID:33770068] |
29. Wang X et al.. (2018) Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.. J Cancer, 9 (8): (1403-1413). [PMID:29721050] |
30. Yan W et al.. (2019) Suppression of SEMA6C promotes preantral follicles atresia with decreased cell junctions in mice ovaries.. J Cell Physiol, 234 (4): (4934-4943). [PMID:30256425] |
31. Sun Y et al.. (2017) TMEM74 promotes tumor cell survival by inducing autophagy via interactions with ATG16L1 and ATG9A.. Cell Death Dis, 8 (8): (e3031). [PMID:29048433] |
32. Liu P et al.. (2021) The NRF2-LOC344887 signaling axis suppresses pulmonary fibrosis.. Redox Biol, 38 (101766). [PMID:33126057] |
33. Chen L et al.. (2021) The Protective Effects of Shengmai Formula Against Myocardial Injury Induced by Ultrafine Particulate Matter Exposure and Myocardial Ischemia are Mediated by the PI3K/AKT/p38 MAPK/Nrf2 Pathway.. Front Pharmacol, 12 (619311). [PMID:33762941] |
34. Li X et al.. (2019) The Specific Inhibition of SOD1 Selectively Promotes Apoptosis of Cancer Cells via Regulation of the ROS Signaling Network.. Oxid Med Cell Longev, 2019 (9706792). [PMID:30911355] |
35. Che L et al.. (2019) Valine increases milk fat synthesis in mammary gland of gilts through stimulating AKT/MTOR/SREBP1 pathway‡.. Biol Reprod, [PMID:30985894] |
36. Zhao M et al.. (2020) Vinpocetine Protects Against Cerebral Ischemia-Reperfusion Injury by Targeting Astrocytic Connexin43 via the PI3K/AKT Signaling Pathway.. Front Neurosci, 14 (223). [PMID:32300287] |
37. Zhu Y et al.. (2020) WISP1 indicates poor prognosis and regulates cell proliferation and apoptosis in gastric cancer via targeting AKT/mTOR signaling pathway.. Am J Transl Res, 12 (11): (7297-7311). [PMID:33312368] |
38. Chen S et al.. (2020) WTAP promotes osteosarcoma tumorigenesis by repressing HMBOX1 expression in an m6A-dependent manner.. Cell Death Dis, 11 (8): (659). [PMID:32814762] |